Glioblastomas (GBM) are brain tumors with a poor prognosis despite treatment that combines surgical resection and radio-chemotherapy. These tumors are characterized by abundant vascularization and significant cellular heterogeneity including GBM stem-like cells (GSC) which contribute to tumor aggressiveness, resistance, and recurrence. Recent data has demonstrated that GSC are directly involved in the formation of new vessels via their transdifferentiation into Tumor Derived Endothelial Cells (TDEC). We postulate that cellular stress such as ionizing radiation (IR) could enhance the transdifferentiation of GSC into TDEC. GSC neurospheres isolated from 3 different patients were irradiated or not and were then transdifferentiated into TDEC. In fact, TDEC obtained from irradiated GSC (TDEC IR+) migrate more towards VEGF, form more pseudotubes in MatrigelTM in vitro and develop more functional blood vessels in MatrigelTM plugs implanted in Nude mice than TDEC obtained from non-irradiated GSC. Transcriptomic analysis allows us to highlight an overexpression of Tie2 in TDEC IR+. All IR-induced effects on TDEC were abolished by using a Tie2 kinase inhibitor, which confirms the role of the Tie2 signaling pathway in this process. Finally, by analyzing Tie2 expression in patient GBMs by immunohistochemistry, we demonstrated that the number of Tie2+ vessels increases in recurrent GBM compared with matched untreated tumors. In conclusion, we demonstrate that IR potentiates proangiogenic features of TDEC through the Tie2 signaling pathway, which indicates a new pathway of treatment-induced tumor adaptation. New therapeutic strategies that associate standard treatment and a Tie2 signaling pathway inhibitor should be considered for future trials.
The primitive tumors of the central nervous system represent ~2–3% of all human cancers. The multiform glioblastoma (GBM), classified as a grade IV astrocytoma according to the classification of the World Health Organization, is the most aggressive and the most frequent of these tumors in adults1. Despite treatments that combine radiotherapy and chemotherapy, average survival still remains between 12 and 15 months2,3,4. One of the main clinical characteristics of these tumors is their recurrence even within the fields of ionizing radiation (IR). The presence of chemo/radioresistant tumor cells could be responsible for these aggressive recurrences. In fact, it is now established that GBM are very heterogeneous tumors, as are most solid cancers5. Recent studies highlight the presence within the tumor of a subpopulation of self-renewing and pluripotent GBM stem-like cells (GSC), also called GBM-initiating cells. These GSC are characterized by their ability to self-renew in vitro (neurosphere formation) and in vivo, by a high expression of neural stem cell markers (i.e. Olig2, Nestin) and stem cell transcription factors (i.e. Sox2, Nanog), their pluripotent aptitude to differentiate into neurons, astrocytes or oligodendrocytes and their high tumorigenic potential in vivo in orthotopically xenografted mice6,7. In addition, the presence of these GSC could explain the high rate of GBM recurrence, since they were shown to be extremely tumorigenic and radioresistant8.
In addition, GBMs are characterized by significant vascularization. The formation of vessels connected to the tumor develops prematurely during tumor progression. This vascularization, although abundant, is morphologically and functionally abnormal and therefore, contributes to the establishment of hypoxia within the tumor, which helps in GSC stemness maintenance. Moreover, GSC are mostly found near vessels within niches formed by endothelial cells9. It has been shown that endothelial cells and GSC establish connections, which are important for GSC stemness maintenance9. Various mechanisms of glioma-associated neovascularization have been described, such as vascular co-option, angiogenesis, vasculogenesis and vascular mimicry10. Furthermore, several teams have shown the existence of cells with endothelial characteristics called Tumor Derived Endothelial Cells (TDEC), which come from the transdifferentiation of GBM cells and more particularly from GSC11,12,13. When GSC were cultured in endothelial media for a few days, they generated cells with phenotypic and functional characteristics of endothelial cells. Moreover, the vessels of tumor xenografts formed by the injection of GSC in immunocompromised mice were primarily composed of human endothelial cells11. This new mechanism of glioma-associated neovascularization could contribute to the failure of the anti-angiogenic therapies (anti-VEGF), which is mainly associated with enhanced invasiveness14.
Considering the importance of vascularization in GBM and in the stemness maintenance of GSC, the capacity of GSC for glio-endothelial transitioning could then participate in the recurrence of GBM after treatment, especially after radiotherapy. In fact, it was shown that IR enhances tumor revascularization15,16. Although the authors showed that the mechanism involved was vasculogenesis, it cannot be excluded that another mechanism might be implicated, such as the transdifferentiation of radioresistant GSC into endothelial cells. Quite recently, our team demonstrated that subtoxic IR exposure of GBM differentiated cells (GDC) isolated from patient tumor resections potentiates the long-term reacquisition of stem-associated properties. These include the ability to generate primary and secondary neurospheres, the expression of stemness markers and an increase in tumorigenicity, which suggest that GBM cells display significant plasticity behavior after cellular stress such as IR17.
Because of the impact of IR on tumor revascularization and on GBM cell plasticity, we hypothesized that IR may impact GSC transdifferentiation into TDEC. Through our work, it is shown for the first time that radiotherapy can promote proangiogenic features of TDEC in GBM in vitro and in vivo, which may participate in tumor revascularization after treatment and finally contribute to in field recurrence of these aggressive cancers.
Materials and methods
Human tumor collection
The study was conducted on newly diagnosed GBM samples isolated from 3 different patients to establish 3 primary GSC cell lines (SRA5, SRB1 and SRC3). All samples were obtained as part of the STEMRI clinical trial (NCT01872221) with written informed consent from patients admitted to the Neurosurgery Department at Toulouse University Hospital and were processed in accordance with the Institution’s Human Research Ethics Committee. Tumors used in this study were histologically diagnosed as grade IV astrocytoma according to the WHO criteria.
Cell culture and treatments
The GBM samples were processed as described previously17,18,19,20 in order to obtain primary neurospheres shown to be enriched in GSC. Neurosphere GSC were maintained in Stem Cell Medium (SCM) at 37 °C in 5% CO2 and were fully characterized in previous works17,18,19,20. These cells were used between the 2nd and 10th passages in order to avoid any stem cell property loss. The stem cell medium was composed of DMEM-F12 (Lonza) supplemented with B27 and N2 (Invitrogen), 25 ng/ml of FGF-2 and EGF (Peprotech).
HUVEC (Human Umbilical Vein Endothelial Cells, Lonza) were cultured in EGM-2 medium (Endothelial Growth Medium, Lonza).
Differentiation was performed according to a previously published protocol adapted as follows17. Briefly, GSC neurospheres were dissociated and then cells were cultured and plated as an adherent monolayer (at least 4 × 103 cells/cm²) in DMEM-F12 supplemented with 15% FCS (Sigma) (Differentiation Medium) for 15 days to ensure optimum differentiation and thereby obtain GDC (Fig. 1a). For transdifferentiation, GSC neurospheres were dissociated and then cells were cultured and plated as an adherent monolayer (at least 4 × 103 cells/cm2) in EGM-2 medium (transdifferentiation medium) for 15 days (Fig. 1a).
After 15 days of culture, the totality of the cells was collected after trypsinization for subsequent experiments.
For Tie2 inhibition analysis, cells were treated with 2 µM of a Tie2 kinase inhibitor (Tie2i) (Abcam) diluted in DMSO for 15 days of transdifferentiation21.
Dissociated GSC were maintained in stem cell medium for 6 h and subjected to a 2, 3 or 2 × 2 Gy IR with a GammaCell Exactor 40 (Nordion). After IR, GSC were kept in stem cell medium for 24 h. Cells were then placed either in (i) differentiation medium, (ii) transdifferentiation medium or (iii) kept in stem cell medium for 15 days. As no significant differences were observed between the different doses of IR tested (data not shown), we only used doses of 2Gy in this paper, which is equivalent to the daily dose used for GBM patients.
Cell proliferation analysis
Cells were plated in 96-well plates at a density of 5 × 103 cells per well and were incubated at 37 °C in 5% CO2 for 24 h. The proliferation ability was assessed by using WST-1 reagent (Roche) and all samples were run in triplicate. WST-1 reagent was added to the wells and cells were incubated for 2 h at 37 °C in 5% CO2. The absorbance was determined with a microplate reader (FLUOstar OPTIMA) at a wavelength of 540 nm.
Quantitative real-time RT-PCR
Total RNA was isolated either from HUVEC, GSC, differentiated or transdifferentiated cells using the RNeasy Plus Mini kit (Qiagen) and then reverse-transcribed using the iScriptTM cDNA synthesis kit (Bio-Rad). Real-time qPCR reactions were tested using SsoFASTTM EvaGreen® Supermix dye (Biorad) and ABI-StepOnePlus Detection System (Applied Biosystems). 18S rRNA (18S) was used as an endogenous control in the ΔCt analysis. The different primers (Eurogentec) used in this study are described in Supplementary Table S1.
Cells were lysed in RIPA buffer complemented with protease and phosphatase inhibitor cocktails (Sigma). Protein content was quantified using Bradford Reagent (Biorad) and 30 µg of protein were then separated on a 7.5 or 10% SDS–PAGE, electroblotted onto PVDF membranes (Amersham). Membranes were then blocked with 10% milk for 1 h. Primary antibodies used for this study are listed in Supplementary Table S2. Primary antibodies were incubated overnight and then the membranes were washed. After incubation with HRP-linked secondary antibodies (anti-mouse (Abcam, 1/10 000), anti-rabbit (Abcam, 1/10 000), the reaction was developed with Western ECL-substrate (Thermo Scientific).
Flow cytometry analyses
For all samples, 2 × 105 cells were first incubated for 30 min in PBS with 10% FCS at 4 °C to avoid nonspecific binding and then incubated with appropriate conjugated primary antibodies for 1 h at 4 °C in the dark. Fluorescence related to immunolabeling was measured using an Accuri C6 flow cytometer (BD Biosciences) and a total of at least 10,000 events were recorded for each sample. The antibodies that were used are indicated in Supplementary Table S2.
Cell culture supernatants were harvested and centrifuged to remove cells and debris. Human Angiopoietin-1 (ANG1) and Angiopoietin-2 (ANG2) ELISA (R&D Systems) were performed according the manufacturer’s instructions. All samples were analysed in duplicate and analyzed with a plate reader (FLUOstar OPTIMA). Readings at 540 nm were subtracted from readings at 450 nm and growth factor amounts were determined using a standard curve.
AcLDL uptake assay
For the AcLDL uptake assay, 10 µg/ml of diI-acLDL (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate - acLDL) (Molecular Probes, Life Technologies) were added to culture medium. The cells were then cultured at 37 °C in 5% CO2 for 4 h [12, 22]. Cells were then washed and fixed in Paraformaldehyde 4% (ChemCruz). After washing, cells were stained with PBS containing 0.1% DAPI for 10 min and fluorescence related to acLDL uptake in cells was observed and photographed (Nikon NIS Element).
Pseudotube formation assay
For pseudotube formation assay, 80 µl of Growth Factor Reduced MatrigelTM (Corning) were dropped into wells of a 96-wells plate and allowed to polymerize for 1 h at 37 °C. Cells were then seeded at 15 × 103 cells per well in a complete medium and allowed to incubate for 24–48 h at 37 °C in 5% CO2. To quantify the pseudotube formation, photographs of at least 3 fields per well were taken (Nikon NIS Element, ×10 magnification) and total pseudotube length was quantified using ImageJ software.
Cell migration assays
Transwell (24 wells, 8 µm pore size, BD Biosciences) cell culture chambers were used. The upper chamber of the inset was seeded with 15 × 103 cells in 100 µl of a serum-free medium (DMEM-F12 for GSC and GDC; EBM-2 for TDEC and HUVEC). The lower chamber was filled with a serum-free medium (DMEM F12 or EBM-2) containing human recombinant-VEGF (50 ng/ml, R&D Systems) or without VEGF as a control. All conditions were duplicated. Cells were allowed to migrate for 5 h at 37 °C in 5% CO2. Non-migrated cells were then removed by wiping the upper side of the membranes with a cotton swab. Transmigrated cells were fixed with Paraformaldehyde 4% (ChemCruz) and stained with Hematoxylin (Merck). The number of transmigrated cells was counted by observation with a Nikon ECLIPSE TS100 microscope. The number of migratory cells was determined by subtracting the number of cells that migrate without VEGF from the number of cells that migrate in the presence of VEGF.
In vivo MatrigelTM Plug Assay
Nude mice were used according to protocol APAFIS#10654-2017071812393169 v2 reviewed and approved by the Institutional Animal Care and Use Committee of the Midi-Pyrénées Region (France).
After 15 days of culture in transdifferentiation medium, 5 × 106 cells were mixed on ice with Growth Factor Reduced MatrigelTM (Corning). A subcutaneous injection of this mix was then administered dorsolaterally in 8-week-old female nude mice. For Tie2 kinase inhibition experiments, the Tie2 kinase inhibitor was diluted in water containing 5% Ethanol and 5% Kolliphor® (Sigma-Aldrich). An intraperitoneal injection of the inhibitor (30 mg/kg) or the vehicle was administered twice a day. After 14 days, mice were sacrificed and the plugs were collected, fixed and embedded in paraffin. For histological analysis, the sections were deparaffinized in xylene, then rehydrated in an ethanol series. Staining with Mayer’s Hematoxylin (Merck) and Eosine-Orange G (Merck) was performed prior to dehydration and mounting with a Eukitt solution. The slides were then observed with a Nikon ECLIPSE TS100 microscope. The number of functional blood vessels was determined by counting the number of blood vessels containing red blood cells on photographs of at least 5 random fields per plug. Images were independently coded and then analysed by at least two experienced members of our laboratory in a blinded manner.
For the immunohistochemistry of patient GBMs, frozen tumor sections were fixed in 95% ethanol. The slides were then rehydrated and antigen retrieval was performed at 96 °C for 20 min using DAKO buffer pH9 (high pH target retrieval solution, DAKO, Glostrup, Denmark). The primary antibody (see Table S2) was incubated for 30 min at room temperature and then washed in PBS. The secondary step was performed with the EnVision FLEX system (DAKO) for 20 min, and after PBS wash, revealed using a peroxidase label that was visualized with diaminobenzidine (DAKO). Slides were counterstained with hematoxylin, dehydrated, and mounted.
Immunofluorescence analysis of MatrigelTM plugs was performed on 5 µm paraffin-embedded sections. Sections were deparaffinized in xylene and rehydrated in an ethanol series. Antigen retrieval was performed at 96 °C for 20 min using DAKO buffer − pH9 and washing done with PBS. For staining, a Tyramide SuperBoostTM kit with AlexaFluorTM 488 Tyramide (Invitrogen) was used as follows. Peroxydase activity was blocked using Blocking Buffer for 60 min at room temperature. Then, sections were incubated with primary antibodies for 60 min at room temperature. The primary antibodies used are indicated in Table S2. After washes in PBS, incubation with the poly-HRP-conjugated secondary antibody was performed for 60 min. Sections were then washed three times in PBS and incubated with Alexa FluorTM 488 tyramide reagent solution. After 5 min, the reaction was stopped with Reaction Stop Reagent and slides were washed with PBS. Cell nuclei were then marked with DAPI (0.1%, Sigma) prior to mounting the slides using DAKO Fluo mounting medium. For vessels counting, images were independently coded and then analysed by at least two experienced members of our laboratory in a blinded manner.
The Affymetrix chips were standardized by the RMA method (R software version 3.3.2, Bioconductor version 3.4). The differences between the different conditions were tested using an ANOVA (R software version 3.3.2) corrected for multiple tests using the Benjamini & Hochberg method. Sample Enrichment Score  were computed using the Autocompare_SES software (available at https://sites.google.com/site/fredsoftwares/products/autocompare_ses) using the “greater” (indicating an enriched gene set) Wilcoxon tests and the GeneOntology C5 , Reactome  databases. The genes of the Tie2 signaling pathway used in Fig. 4b are ANGPT2, ANGPT4, DOK2, GRB14, GRB2, GRB7, HRAS, KRAS, NRAS, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PTPN11, SHC1, SOS1 and TEK. All data are available at the National Center of Biotechnology Information (NCBI) GEO Database under the series number GSE138236.
For cell culture, each individual experiment was repeated at least three times. Where appropriate, mice were randomized into experimental groups by random number generator. Statistical power was determined from prior studies from our laboratories using similar models/cells [18, 26]. Data were normalized, as appropriate, to means of each experiment with the reference condition set at 1. Experimental data were analysed by unpaired two-tailed t-test (for Figs. 1–5) or with matched-pairs non-parametric Wilcoxon Signed Rank test (for Fig. 6). Results are expressed as mean ± SEM. Differences were deemed significant when P < 0.05. These analyses were performed using Prism, Version 5.00 (GraphPad Software) or STAT VIEW software package (SAS, Cary, NC).
GSC transdifferentiation to TDEC
To study the transdifferentiation of GSC to TDEC, we used three different primary GSC (SRA5, SRB1 and SRC3) established from 3 patients’ surgical GBM samples that are fully characterized in our previous works17,18,19,20. Therefore, we cultured our GSC in EGM-2 and analyzed the TDEC obtained for endothelial characteristics (Fig. 1). As previously described, TDEC significantly overexpressed RNA and protein of CD31 compared to GDC or GSC (Fig. 1b–d)11. In addition, as expected, TDEC lost the expression of stem cells markers (Supp Fig. S1a, b). The expression of TUJ1 was also significantly lower in TDEC SRA5 compared to GDC SRA517. In TDEC SRB1 and TDEC SRC3, TUJ1 expression tends to be lower than in GDC SRB1 and GDC SRC3 but this decrease was not significant. HUVEC also expressed RNA and protein of this marker suggesting that other cells like endothelial cells could also express TUJ1 (Supp Fig. S1a, b). The expression of VEGFR2, the main VEGF receptor, was not significantly different between GSC, GDC and TDEC obtained from SRA5 and SRB1. TDEC obtained from SRC3 GSC expressed significantly more VEGFR2 than SRC3 GSC but the difference was not significant between TDEC and GDC (Supp Fig. S1a). In fact, VEGFR2 is expressed in endothelial cells but many articles indicate that it is expressed in tumor cells and notably in glioma cells27.
Furthermore, the expression of smooth muscle cells or pericyte markers (NG2, PDGFRβ, α-SMA, and Calponin) in TDEC from SRA5, SRB1 and SRC3 GSC was lower or not different from the expression of these markers detected in GDC, which confirms that our protocol made it possible to obtain endothelial-like cells and not mural-like cells (Supp Figs. S1a and S2a–c).
However, TDEC obtained from the 3 GSC acquired specific functional characteristics of endothelial cells such as migration to VEGF in the Boyden Chamber, pseudotube formation in MatrigelTM (Fig. 1e, f and Supp Fig. S3) and acLDLuptake (Supp Fig. S4). In fact, we observed a significant increase in TDEC migration towards VEGF compared to GDC or GSC migration of each cell line (Fig. 1e). TDEC were able to form branched structures and pseudotubes in MatrigelTM in contrast to GSC or GDC (Fig. 1f and Supp Fig. S3). The total line length measured for each TDEC cell line was significantly higher in TDEC compared to that in GDC or GSC and was similar to the total line length measured with HUVEC (Fig. 1f). Finally, TDEC obtained from each GSC were able to uptake acetylated low-density lipoprotein (LDL) (Supp. Fig. S4), a specific endothelial capacity22.
Ionizing radiation potentiates TDEC proangiogenic features
To evaluate the impact of IR on TDEC angiogenic features, the 3 different GSC were or were not subjected to a clinical 2-Gy IR and placed 15 days in EGM2 in order to transdifferentiate them into TDEC (Fig. 2a). For the sake of clarity, henceforward, TDEC obtained from non-irradiated GSC will be referred to as TDEC IR− and TDEC obtained from irradiated GSC will be referred to as TDEC IR+. As shown in Fig. 2b, the expression of CD31 RNA was significantly increased in TDEC IR+ obtained from SRA5 but not from SRB1 and SRC3. Neither CD31 protein expression nor the number of CD31+ cells measured by flow cytometry were significantly increased in TDEC IR+ from SRA5, SRB1 and SRC3 compared to that of TDEC IR− (Fig. 2c, d). Therefore, IR does not increase the number of TDEC obtained from GSC. In parallel, we also confirmed that irradiation of GSC did not affect the RNA or protein expression of stem cell markers (Sox2, Olig2 and NG2) or of differentiated markers (TUJ1) in GSC, in GDC and in TDEC obtained from these 3 GSC (Supp Fig. S5a, b). Moreover, IR did not induce CD31 expression in GSC or GDC of any of the 3 GSC (Supp Fig. S6).
Nonetheless, although IR did not impact the expression of endothelial markers by TDEC, we looked at their specific endothelial abilities such as migration towards VEGF or pseudotube formation in MatrigelTM. In fact, we observed a significant increase in TDEC IR+ migration towards VEGF compared to TDEC IR− obtained from SRA5, SRB1 and SRC3 GSC (P < 0.05, P < 0.05 and P < 0.01, respectively) (Fig. 2e) Moreover, IR significantly increased the ability of TDEC IR+ SRA5, SRB1 and SRC3 to form pseudotubes in MatrigelTM compared to TDEC IR− SRA5, SRB1 and SRC3 (P < 0.05, P < 0.05 and P < 0.01, respectively) (Fig. 2f). These effects were not due to an increase in TDEC proliferation because we confirmed that it was not altered by IR (Supp Fig. S7). Overall, the results of functional tests suggest that IR potentiates the proangiogenic abilities of TDEC obtained after transdifferentiation of GSC.
To confirm our results obtained in vitro in in vivo, we used the well-described MatrigelTM plug assay model. Plugs with TDEC IR+ or TDEC IR− were implanted subcutaneously in nude mice and were recovered after 14 days. We then quantified blood vessel ingrowth by counting functional blood vessel (i.e. with red blood cells inside) in each plug (Fig. 3a). As shown in Fig. 3b, plugs with TDEC IR+ contained significantly more functional blood vessels than the MatrigelTM plugs with TDEC IR− (13.18 ± 4.37 vs 36.26 ± 4.83 vessels/mm2, P < 0.05). To decipher the origin of the vessels observed in each plug, we performed an immunofluorescence assay using a specific anti-human CD31 (hCD31) antibody, which does not stain mouse vessels (Supp Fig. S8). As expected, vessels observed inside the plugs were human vessels labelled by specific anti-hCD31 antibody (Fig. 3a). Therefore, we quantified the number of hCD31+ vessels in all plugs and detected more hCD31+ vessels in plugs with TDEC IR+ compared to plugs with TDEC IR- (Fig. 3c). All these data show that IR potentiates in vitro and in vivo proangiogenic features of TDEC obtained from GSC.
Involvement of the Tie2 signaling pathway
To decipher the IR-induced transdifferentiation pathways, we performed a transcriptomic analysis which identified that a broad range of specific endothelial genes were upregulated in TDEC obtained from the transdifferentiation of GSC, whereas specific stem cell genes and specific genes of differentiated brain cells were downregulated (Fig. 4a). Interestingly, this transcriptomic analysis allowed us to highlight a clear overexpression of Tie2 in TDEC IR+ compared to TDEC IR−. Similarly, the Sample Enrichment Score analysis of the Tie2 signaling pathway indicated that it was significantly upregulated in TDEC IR+ compared to TDEC IR− (Fig. 4b). To confirm these results, Tie2 RNA expression was evaluated by RT-qPCR in TDEC IR− and TDEC IR+ obtained from SRA5, SRB1 and SRC3 GSC. As shown in Fig. 4c, Tie2 RNA was significantly increased in TDEC IR+ obtained from the 3 GSC compared to that in TDEC IR−. Therefore, we looked at the expression of the Tie2 protein and we also found a significant augmentation of its expression in TDEC IR+ compared to TDEC IR− (Fig. 4d). We also examined the activation of Tie2 via phosphorylation. Phosphorylated-Tie2 (P-Tie2)/GAPDH ratio was significantly increased in all three TDEC IR+ compared to TDEC IR− (Fig. 4e). We did not find an increase in the ratio P-Tie2/Tie2, which suggests that the increase in the P-Tie2/GAPDH ratio was due to the increase in Tie2 expression (Supp Fig. S9). Furthermore, IR did not impact RNA expression of angiopoietin-1 (ANG1) and -2 (ANG2), the two ligands of Tie2, in TDEC IR+ compared to TDEC IR− (Supp Fig. S10a, b). In fact, we detected no difference in ANG1 and ANG2 protein levels in supernatants between TDEC IR+ and TDEC IR- (Supp Fig. S10c, d). Tie2 activation may act either via AKT or via ERK pathways. Thus, we then looked at these signaling pathways28,29. We identified specific activation of the AKT pathway in TDEC IR+ compared to TDEC IR− (Fig. 4f). We notice no difference in ERK pathway activation between TDEC IR+ and TDEC IR− obtained from the 3 GSC (Fig. 4g).
Therefore, our results showed a significant increase in Tie2 and AKT signaling pathway activation in TDEC IR+, which could explain the effect of IR on the proangiogenic abilities of TDEC IR+.
Tie2 signaling pathway inhibition decreases IR-induced potentiation of TDEC angiogenic features
To confirm that the Tie2 signaling pathway was involved in IR-induced proangiogenic abilities of TDEC IR+, we decided to inhibit Tie2 activation using a specific Tie2 kinase activity inhibitor (Tie2i)21. Using HUVEC, we identified the dose of 2 µM of Tie2i as the optimal concentration required to inhibit the Tie2 signaling pathway (Supp Fig. S11a). Likewise, in the presence of 2 µM of Tie2i, phosphorylation of AKT was clearly decreased in TDEC IR− and in TDEC IR+ (Supp Fig. S11b). Therefore, we inhibited the Tie2 signaling pathway in TDEC IR+ in order to ascertain whether the inhibition of this specific signaling pathway could modify the proangiogenic abilities induced by IR. The inhibition of the Tie2 signaling pathway significantly decreased the expression of CD31 RNA in all TDEC IR− and TDEC IR+ except in TDEC IR+ SRC3 (Fig. 5a). Similarly, Tie2i induced a significant decrease in the number of CD31+ TDEC obtained from non-irradiated SRA5 and SRB1 GSC, but not from non-irradiated SRC3 GSC (Fig. 5b). However, Tie2i significantly decreased the CD31+ TDEC obtained from all 3 irradiated GSC. As shown in Fig. 5c, Tie2i significantly decreased migration of TDEC IR− SRA5 and SRC3 but not of TDEC IR- SRB1, whereas it significantly decreased migration of TDEC IR+ obtained from all 3 GSC. Interestingly, Tie2i did not influence pseudotube formation of all TDEC IR−, but it significantly decreased pseudotube formation of all 3 TDEC IR+ (Fig. 5d). The proliferation of TDEC IR− and TDEC IR+ was not influenced by Tie2i (Supp Fig. S12). All these results show that, without IR, the Tie2 signaling pathway is involved in transdifferentiation but is not essential for the acquisition of proangiogenic features by TDEC, whereas it plays a crucial role in the IR-induced potentiation of in vitro proangiogenic features of TDEC and particularly in pseudotube formation.
To confirm this important role of the Tie2 signaling pathway, we performed the MatrigelTM plug assay in the presence of Tie2i with TDEC IR+. After subcutaneous implantation of the plugs containing the cells, the mice were injected twice daily with the vehicle or the Tie2i for 14 days21. As was previously observed, we found more functional blood vessels in plugs with TDEC IR+ control in comparison to plugs with TDEC IR− control (mean: 76.65 ± 7.34 vs 41.2 ± 7.04 vessels/mm2, P < 0.01) (Fig. 5e, f). Interestingly, plugs with TDEC IR+ with Tie2i had significantly fewer functional blood vessels than plugs with TDEC IR+ control (24.54 ± 6.81 vs 76.65 ± 7.34 vessels/mm2, P < 0.001). The number of hCD31+ vessels was also lower in plugs with TDEC IR+ with Tie2i compared to plugs with TDEC IR+ control (Fig. 5g).
All these results suggest that the Tie2 signaling pathway is a key actor of IR-induced potentiation of the proangiogenic features of TDEC.
Tie2 expression is increased in GBM after treatment
To investigate whether these results were clinically relevant, we collected 6 matched GBM tissues from the initial surgery of untreated tumors and from the second surgery after treatment failure with IR and temozolomide chemotherapy, to evaluate Tie2 expression by immunohistochemistry analysis. Although the number of Tie2+ positive vessels varied among the GBM tissues from the initial surgeries, we observed a significant increase of Tie2+ vessels in recurrent tumors compared to naive tumor sections (Fig. 6a, b). Collectively, Tie2 is upregulated in GBM collected after radiotherapy compared to initial GBM biopsies. This result indicates that Tie2-mediated IR-induced potentiation of proangiogenic features of TDEC can also arise in patients. Therefore, this mechanism could play an important role in tumor recurrence after conventional treatment.
Radiotherapy is a central treatment for GBM. The protocol described by Stupp et al which combines concomitant chemotherapy with temozolomide and radiotherapy (30 daily fractions of 2 Gy) has been the standard of care for patients with GBM for more than a decade since it made it possible to increase the median survival from 12.1 to 14.6 months3,4. However, relapse is almost inevitable and mainly occurs at the initial tumor location within the radiation field. The identification of the mechanisms involved in GBM relapse is essential to increase the efficacy of radiotherapy in GBM and thereby increase the overall survival of patients. Here, we report for the first time that 2 Gy irradiation (equivalent to the daily dose used) potentiates proangiogenic features of TDEC in vitro and in vivo through the Tie2 signaling pathway.
It is known that GBM recurrence is preceded by the implementation of a new tumor vasculature30. Given the high dose and the wide field of radiation delivered to brain tumors, it is unlikely that any endothelial cells in the tumor could survive31. In fact, two articles have shown that irradiation of mice brain tumors induced neovascularization via vasculogenesis15,16. Moreover, De Pascalis et al. reported that the percentage of CD31+ cells carrying the same genomic alteration as tumor cells was increased in recurrent tumors compared to primary tumors, which suggests that tumor-derived endothelium plays a role in neo-vascularization32. In keeping with this report, we show that an increase in the proangiogenic feature of TDEC obtained from GSC transdifferentiation may also participate in IR-induced neovascularization.
Different authors have shown that GBM cells, and in particular GSC, display significant plasticity11,12,13,17,33. GSC transdifferentiation into endothelial cells is a mechanism which has been described and demonstrated in numerous papers11,12,13,14. In addition, it was has been shown that GSC can transdifferentiate into other mesenchymal cells such as smooth muscle-like cells or vascular mural-like cells33,34. El Hallani et al found that only few CD133+ GSC were able to transdifferentiate into smooth muscle-like cells in vitro which can form tubular structures in MatrigelTM30. Scully et al found that GSC could transdifferentiate into vascular mural-like cells to develop vascular mimicry33. In these studies, the authors showed that these cells expressed smooth muscle cells or pericyte markers like α-SMA, NG2, or PDGFRβ but expressed no endothelial cell-specific markers such as CD31 or Tie2. In our work, TDEC clearly expressed the endothelial markers CD31 and Tie2 but the expression of smooth muscle cell or pericyte markers (NG2, PDGFRβ, α-SMA and Calponin) is not significantly different from that observed in GDC (Supp Figs. S1 and S2). Moreover, we demonstrated that GDC obtained from the 3 GSC were not able to produce tubular formations when cultured on MatrigelTM, which indicates that GDC are not smooth muscle-like cells or vascular mural-like cells17,33,34.
To highlight a specific target involved in IR-induced potentiation of proangiogenic features of TDEC, we performed a transcriptomic analysis. In this study, we showed that Tie2 expression as well as the activation of the Tie2 signaling pathway is markedly enhanced in TDEC IR+ compared to TDEC IR−. Tie2 is a tyrosine kinase receptor and is mainly expressed by endothelial cells. Disrupting Tie2 function in mice results in embryonic lethality with defects in embryonic vasculature35. Of the three known Tie2 ligands, ANG1 and ANG2 are most often described. In cancer, the Tie2/ANG signaling pathway is clearly involved. For example in GBM, the levels of ANG1, ANG2 and phosphorylated-Tie2 are higher than in normal brain36,37. In our study, we clearly demonstrated an increase in Tie2 expression and activation together with an increase in AKT phosphorylation in TDEC IR+, but we showed no difference in ANG1 and ANG2 level, which suggests that the increase in Tie2 activation is mainly due to the increase in its expression. We confirmed that Tie2 activation is involved in IR-induced effect on endothelial features of TDEC by using a specific Tie2 kinase inhibitor in vitro and in vivo. Considering that almost all vessels observed in the plugs were of human origin, it can be assumed that GSC could transdifferentiate into macrophage-like cells since they also express CD31 and Tie2. To our knowledge, the transdifferentiation of GSC into hematopoietic cells such as macrophages has never been described. Furthermore, we detected no increase in macrophage markers (such as CD45, CD68, CD11b or CD14) in TDEC compared to GDC or GSC using the transcriptomic chip data.
Finally, this process of GSC response to radiotherapy, which might allow radioresistant GSC to form new vessels via their transdifferentiation into TDEC, could contribute to the initiation of the tumor recurrence after treatment. In fact, a recent paper using a three dimensional mathematical model, reported that a combinatorial regimen composed of standard treatment currently used (radiotherapy, temozolomide, bevacizumab…) combined with a treatment that would target GSC transdifferentiation into TDEC, could reduce both tumor size and invasiveness and could lead to tumor eradication38. Consequently, it would be of great interest to inhibit this particular IR-induced potentiation of the endothelial features of TDEC in order to improve and optimize the treatment of this aggressive brain tumor. It is interesting to note that very recently it was shown that Regorafenib, a pan-tyrosine kinase inhibitor which also targets Tie2, increases the overall survival of patients with recurrent GBM compared to lomustine, which suggests that this efficacy could in part be due to the increase in Tie2 expression after IR that we described39. One might put forward that a combination of IR and Regorafenib, which is currently used in the treatment of metastatic colorectal cancer and gastro intestinal stromal tumors, would be an interesting combination for the treatment of primitive GBM.
Overall, our data highlight the existence of a new mechanism of radioresistance in GBM through the transdifferentiation of the surviving GSC after treatment, which leads to the formation of a new tumor vasculature. The IR-induced potentiation of the proangiogenic features of TDEC appeared to be supported by the Tie2 signaling pathway. New therapeutic strategies that combine radiotherapy/temozolomide and a Tie2 signaling pathway inhibitor should be considered for future trials.
Louis, D., Ohgazi, H., Wiestler, O. & Cavenee, W. Diffuse astrocytic and oligodendroglial tumours. World Health Organization Histological Classifications of Tumours of the Central Nervous System. (4th ed., Revised. Lyon: International Agency for Research Centre; 2016).
Park, D. M., Sathornsumetee, S. & Rich, J. N. Treatment and management of malignant gliomas: medical oncology. Nat. Rev. Clin. Oncol. 7, 75–77 (2010).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl. J. Med. 352, 987–996 (2005).
Stupp, R., Hegi, M. E. & Mason, W. P. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Tang, D. G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 22, 457–472 (2012).
Cheng, L., Bao, S. & Rich, J. N. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochemical Pharmacol. 80, 654–665 (2010).
Tchoghandjian, A. et al. A2B5 cells from human glioblastoma have cancer stem cell properties: A2B5 cells in glioblastoma. Brain Pathol. 20, 211–221 (2010).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007).
Hardee, M. E. & Zagzag, D. Mechanisms of glioma-associated neovascularization. Am. J. Pathol. 181, 1126–1141 (2012).
Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824–828 (2010).
Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829–833 (2010).
Soda, Y. et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl Acad. Sci. USA 108, 4274–4280 (2011).
Soda, Y., Myskiw, C., Rommel, A. & Verma, I. M. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J. Mol. Med. 91, 439–448 (2013).
Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig. 120, 694–705 (2010).
Wang, S.-C., Yu, C.-F., Hong, J.-H., Tsai, C.-S. & Chiang, C.-S. Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS ONE 8, e69182 (2013).
Dahan, P. et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 5, e1543–e1543 (2014).
Malric, L. et al. Inhibiting integrin β8 to differentiate and radiosensitize glioblastoma-initiating cells. Mol. Cancer Res. 17, 384–397 (2019).
Gouazé-Andersson, V. et al. FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker. Oncotarget 9, 31637–31649 (2018).
Kowalski-Chauvel, A. et al. Alpha-6 integrin promotes radioresistance of glioblastoma by modulating DNA damage response and the transcription factor Zeb1. Cell Death Dis. 9, 872 (2018).
Semones, M. et al. Pyridinylimidazole inhibitors of Tie2 kinase. Bioorg. Medicinal Chem. Lett. 17, 4756–4760 (2007).
Voyta, J. C., Via, D. P., Butterfield, C. E. & Zetter, B. R. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J. Cell Biol. 99, 2034–2040 (1984).
Tosolini, M. et al. Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. OncoImmunology 5, e1188246 (2016).
Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nature Genetics 25, 25-29 (2000).
Milacic, M. et al. Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome. Cancers 4, 1180-1211 (2012).
Evrard, S. M. et al. The profibrotic cytokine transforming growth factor-β1 increases endothelial progenitor cell angiogenic properties. J Thromb Haemost. 10, 670-679 (2012).
Kessler, T. et al. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget 6, 31050–31068 (2015).
DeBusk, L. M., Hallahan, D. E. & Lin, P. C. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp. Cell Res. 298, 167–177 (2004).
Harfouche, R. et al. Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases1. The FASEB J. 17, 1523–1525 (2003).
Kim, H. S. et al. Which Combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology 273, 831–843 (2014).
Mao, X. W. A Quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation. Technol. Cancer Res. Treat. 5, 127–134 (2006).
De Pascalis, I. et al. Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. Mod. Pathol. 31, 1361–1366 (2018).
Scully, S. et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J. Neurosci. 32, 12950–12960 (2012).
El Hallani, S. et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133, 973–982 (2010).
Sato, T. N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74 (1995).
Huang, H., Bhat, A., Woodnutt, G. & Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10, 575–585 (2010).
Ding, H. et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-Oncol. 3, 1–10 (2001).
Yan, H. et al. 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy. Cancer Res. 77, 4171–4184 (2017).
Lombardi, G. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 20, 110–119 (2019).
We would like to thank Dina Ferreira Da Mota (Paul Sabatier University, Toulouse), Laetitia Ligat and Manon Farcé (INSERM U1037, Technology Cluster) for their technical assistance, the animal facility (CREFRE) (Sarah Gandarillas) and Julia Gilhodes at the Department of Biostatistics (IUCT-Oncopole). P. Deshors was supported by a PhD fellowship from the Ministère de l’Enseignement Supérieur et de la Recherche and from la Ligue Nationale contre le Cancer. This research was funded by la Ligue Régionale contre le Cancer (Hautes Pyrénées and Haute Garonne committees), by the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Plan Cancer/ITMO HTE (tumor heterogeneity and ecosystem) program (MoGlimaging).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by D. Aberdam
About this article
Cite this article
Deshors, P., Toulas, C., Arnauduc, F. et al. Ionizing radiation induces endothelial transdifferentiation of glioblastoma stem-like cells through the Tie2 signaling pathway. Cell Death Dis 10, 816 (2019). https://doi.org/10.1038/s41419-019-2055-6
Dual role of WNT5A in promoting endothelial differentiation of glioma stem cells and angiogenesis of glioma derived endothelial cells
Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells
Scientific Reports (2021)
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
Cell Death & Disease (2021)
Human urine-derived stem cell-derived exosomal miR-21-5p promotes neurogenesis to attenuate Rett syndrome via the EPha4/TEK axis
Laboratory Investigation (2021)
Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas
Journal of Experimental & Clinical Cancer Research (2020)